Macular telangiectasia type 2 (MacTel) has traditionally been considered a rare retinal disease. But how rare it actually is has been surprisingly difficult to pin down.
Now, a large U.S. electronic health record analysis suggests diagnosed MacTel prevalence has risen considerably over the past decade. In fact, its rate of increase from 2015 to 2024 exceeded that of age-related macular degeneration (AMD) over the same period.
First, some background: Why has MacTel prevalence been difficult to estimate?
MacTel is a bilateral, progressive neurodegenerative retinal disease characterized by parafoveal telangiectatic changes and progressive disruption of the ellipsoid zone.
The problem? Early disease can be subtle.
Much of the older epidemiological evidence relied on color fundus photography.
For example:
- The Melbourne Collaborative Cohort Study estimated MacTel prevalence at approximately 5 to 23 cases per 100,000 people using nonmydriatic digital fundus photography.
- Meanwhile, the Beaver Dam Eye Study reported a substantially higher prevalence of approximately 100 cases per 100,000.
Take note: Both studies relied heavily on fundus photography, which may miss subtle manifestations of MacTel.
And the current approach?
Today, imaging modalities including optical coherence tomography (OCT), fundus autofluorescence and OCT angiography can provide additional information that helps clinicians recognize and characterize MacTel, including earlier disease.
So with this in mind: Researchers wanted to know what MacTel prevalence looks like in a more contemporary clinical population.
Let’s talk study details.
The cross-sectional study used aggregated, de-identified electronic health record (EHR) data from the TriNetX platform spanning 2015 through 2024.
Researchers identified adults ages 35 and older with an ICD-10 diagnosis code corresponding to MacTel and calculated prevalence for each year.
They then broke prevalence down according to age, sex, race and ethnicity.
And because the researchers wanted some context for the change over time, they compared the ratio of change in MacTel prevalence with the change in AMD prevalence during the same 10-year period.
Who were the patients included in this analysis?
A couple of notes:
- The analysis drew from a large U.S. EHR network containing data for more than 88 million patients across 50 healthcare organizations.
- Because researchers calculated prevalence separately for each year, the study didn't report a single cumulative number of unique patients included from 2015 through 2024.
For context: In 2024, the study population included approximately 51 million patients, including 4,621 patients ages 35 and older with an ICD-10 diagnosis code for MacTel.
Rather than identifying MacTel through independent image grading or examination, researchers relied on diagnoses already recorded within patients' EHRs.
That distinction becomes important when interpreting the findings.
And how much did MacTel prevalence change?
MacTel prevalence increased from 4.75 cases per 100,000 patients in 2015 to 9.06 per 100,000 in 2024.
- That's a 1.91-fold increase over the study period (95% confidence interval [CI], 1.79–2.03).
Interestingly, MacTel's increase was greater than the change observed for AMD over the same period.
The ratio of change for MacTel compared with AMD produced an odds ratio (OR) of 1.25 (95% CI, 1.17–1.33).
In other words: Diagnosed MacTel prevalence didn't simply increase alongside another common retinal condition—its relative increase was greater.
Did prevalence differ among patient groups?
Yes. Women had 1.19 times greater odds of MacTel compared with men (95% CI, 1.16–1.21), and women accounted for approximately 60% of MacTel diagnoses.
Age also mattered.
Patients ages 65 to 74 had the highest prevalence at 15.43 cases per 100,000, followed by adults 75 and older at 14.73 per 100,000.
Researchers also identified differences by race.
Using White patients as the reference group, White patients had greater odds of MacTel compared with Black patients (OR, 2.10; 95% CI, 2.01–2.20) and Asian patients (OR, 1.16; 95% CI, 1.09–1.22).
Any limitations to keep in mind?
Definitely.
Since this was an EHR-based analysis, a MacTel diagnosis depended on the presence of an ICD-10 code rather than standardized review of retinal imaging.
That means the study measured documented clinical diagnoses, not MacTel identified through systematic screening of the underlying population.
As a result, changes in coding, disease awareness, access to eyecare and adoption of retinal imaging could all influence the apparent prevalence over time.
The design also can't inform investigators that MacTel itself became biologically more common between 2015 and 2024.
And while the database provided an extremely large sample, EHR-based demographic comparisons may also reflect differences in healthcare access, diagnosis, and documentation among patient populations.
So, what might explain the increase?
The researchers point to one particularly plausible factor: better detection.
MacTel can be difficult to identify during its earlier stages using fundus photography alone. Meanwhile, modern OCT and other multimodal retinal imaging techniques have become increasingly integrated into routine eyecare.
That raises an important possibility: At least some of the nearly two-fold increase may represent clinicians getting better at finding disease that was previously missed.
So, the rising prevalence shouldn't automatically be interpreted as evidence that MacTel itself has suddenly become more common.
Take home.
Improvements in OCT and multimodal retinal imaging, greater disease awareness, and increased recognition of earlier MacTel may be helping clinicians identify cases that previously went undiagnosed.
For eyecare providers, these findings may be the bigger story: MacTel remains uncommon, but we're getting considerably better at finding it.